Federal Circuit upholds two patent decisions over Copaxone

15-10-2018

Federal Circuit upholds two patent decisions over Copaxone

ericsphotography / iStockphoto.com

The US Court of Appeals for the Federal Circuit has upheld two decisions that said patents relating to the dosage of Teva’s Copaxone (glatiramer acetate) 40mg/mL treatment are invalid.


patent, patent invalidity, generics, appeal, US Court of Appeals for the Federal Circuit, Teva Pharmaceuticals, Mylan, Yeda Research & Development, Sandoz

More on this story

Alvogen launches Copaxone generic
06-09-2016

EPO upholds Copaxone patent
28-05-2014

LSIPR